Ignite Creation Date:
2024-05-06 @ 6:57 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05846516
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-04-18
Brief Title:
A Study to Evaluate ATP150ATP152 VSV-GP154 and Ezabenlimab in Patients With KRAS G12DG12V Mutated PDAC KISIMA-02
Sponsor:
Organization:
Amal Therapeutics
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
85
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: